Also trades as: SABSW (NASDAQ) · $vol 0M
SABS NASDAQ
SAB Biotherapeutics, Inc.
1W: -9.4%
1M: -20.5%
3M: -24.0%
YTD: -20.9%
1Y: +50.5%
3Y: -36.3%
5Y: -97.0%
$2.98
-0.08 (-2.61%)
Weekly Expected Move ±4.6%
$3
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships0
As Filer
counterparties named
5
As Counterparty
mentioned by others
2021-06-22
Earliest Filing
2025-02-05
Latest Filing
Mentioned As Counterparty
5 mentionsOther companies that named SABS in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| SABSW SAB Biotherapeutics, Inc. | partner | Lease agreement for office and laboratory space | 2025-02-05 | View |
| SABSW SAB Biotherapeutics, Inc. | partner | Lessee in lease agreement and issuer of convertible promissory note | 2022-10-13 | View |
| SABSW Big Cypress Acquisition Corp. | acquirer | Target company in the proposed business combination with BCYP | 2021-10-12 | View |
| SABSW Big Cypress Acquisition Corp. | acquirer | Target company being acquired in the merger agreement. | 2021-08-16 | View |
| SABSW Big Cypress Acquisition Corp. | acquirer | Target company in the Merger Agreement | 2021-06-22 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR